# EDGAR Filing Document

**Accession Number:** 0001551986
**File Stem:** 0001551986-23-000008
**Filing Date:** 2023-3
**Character Count:** 4269
**Document Hash:** 76888840c5cc6da74e251aaeb5608848
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001551986-23-000008.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001551986-23-000008

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Other Events

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 9 METERS BIOPHARMA, INC.
- **CENTRAL INDEX KEY:** 0001551986
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 273948465
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37797
- **FILM NUMBER:** 23725806

**BUSINESS ADDRESS:**
- **STREET 1:** 4509 CREEDMOOR ROAD
- **STREET 2:** SUITE 201
- **CITY:** RALEIGH
- **STATE:** NC
- **ZIP:** 27612
- **BUSINESS PHONE:** 919-275-1933

**MAIL ADDRESS:**
- **STREET 1:** 4509 CREEDMOOR ROAD
- **STREET 2:** SUITE 201
- **CITY:** RALEIGH
- **STATE:** NC
- **ZIP:** 27612

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INNOVATE BIOPHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20180201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Monster Digital, Inc.
- **DATE OF NAME CHANGE:** 20150930

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tandon Digital, Inc.
- **DATE OF NAME CHANGE:** 20120611

?xml version="1.0" ? nmtr-20230313

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): March 13, 2023**

**9 Meters Biopharma, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37797** | **27-3948465** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(Commission<br>File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

**8480 Honeycutt Road, Suite 120, Raleigh, NC 27615**

**(Address of principal executive offices) (Zip Code)**

**(919) 275-1933**

**(Registrant's telephone number, include area code)**

**N/A**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock $0.0001 Par Value | NMTR | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

------

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

| | |
|:---|:---|
| **Item 8.01.** | **Other Events.** |

---

9 Meters Biopharma, Inc. confirms it does not hold any deposits or securities or maintain any accounts at Silicon Valley Bank.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | 9 Meters Biopharma, Inc. | 9 Meters Biopharma, Inc. |
| Date: March 13, 2023 | By: | /s/ Bethany Sensenig |
|  |  | Bethany Sensenig |
|  |  | Chief Financial Officer |

---